Mr. McAdams, Mr. Collins’s spokesman, said the private placement was available to qualified American investors and said Mr. Hook had previously invested in a private placement with the company in 2009, before Mr. Collins was a congressman. Several other investors were longtime friends of Mr. Collins, Mr. McAdams said, and their investment predates his time in Congress. Mr. Quinn dismissed questions about whether anyone engaged in insider trading and said the company’s stock had been rising in anticipation of the results of the clinical trial later this year. The outcome of such trials is typically kept secret from investors and even company executives. 